RT Journal Article
SR Electronic
T1 The relationship between anxiety and levels of Alzheimer’s disease plasma biomarkers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.09.24310168
DO 10.1101/2024.07.09.24310168
A1 Bernard, Mark A.
A1 Boutajangout, Allal
A1 Debure, Ludovic
A1 Ahmed, Wajiha
A1 Briggs, Anthony Q.
A1 Boza-Calvo, Carolina
A1 Vedvyas, Alok
A1 Marsh, Karyn
A1 Bubu, Omonigho M.
A1 Osorio, Ricardo S.
A1 Wisniewski, Thomas
A1 Masurkar, Arjun V.
YR 2024
UL http://medrxiv.org/content/early/2024/07/10/2024.07.09.24310168.abstract
AB Anxiety is highly prevalent in Alzheimer’s disease (AD), correlating with CSF/PET biomarkers and disease progression. Relationships to plasma biomarkers are unclear. Herein, we compare levels of plasma biomarkers in research participants with and without anxiety at cognitively normal, mild cognitive impairment, and AD dementia stages. We observed significantly higher plasma tau/Aβ42 ratio in AD participants with anxiety versus those without, but did not observe differences at other stages or plasma biomarkers. No such relationships were evident with depression. These results support a unique pathophysiological relationship between anxiety and AD that can be reflected in plasma biomarkers, suggestive of heightened neurodegeneration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH P30AG066512 and the Louis J. And June E. Kay Foundation. Omonigho M. Bubu additionally receives funding support from NIA (L30AG064670, K23AG068534, R01AG082278, RF1AG083975), Alzheimer's Association (AARG-D-21-848397), American Academy of Sleep Medicine (AASM-231-BS-20), and BrightFocus Foundation (BrightFocus-ADR-22-924755), Thomas Wisniewski receives additional funding from NIA P01AG060882. Anthony Q. Briggs receives additional funding from Alzheimer's Association (AARF-D-24-1243696).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of New York University Grossman School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data supporting the findings of this study are available upon request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.